http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011202125-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_22de09179568d25ff393709a7d009821
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-606
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-258
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-252
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-10
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-82
filingDate 2008-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72e89442bd91b90a40c0664eaaf6582e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f38d7054bbbadd28b3c89b0b7d80da77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00e1625e981145a65f0ef5251284c834
publicationDate 2011-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2011202125-A1
titleOfInvention Artificial stent and its preparation method
abstract An artificial stent and its preparation method. The artificial stent comprises a stent body and a coating on it. The artificial stent is characterized in that the coating comprises a drug-loaded layer containing silk fibroin and a drug. The drug-loaded layer has a microporous structure substantially consists of silk fibroin and loaded with the drug. The microporous structure is obtained by a method comprising: uniformly coating the surface of the stent body with a solution of silk fibroin, denaturing by heat or chemical reagents; soaking the stent with purified water; then freeze drying and warming-drying, so as to from a microporous structure of the coating; loading the drug into the micropores in the coating; and removing the stent and drying. Silk fibroin used to coat the stent is a natural bio-material with great bio-compatibility; an can be absorbed and metabolized slowly by human body without adverse side effects, overcoming certain adverse effects of conventional drug-coated stents.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9433709-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016067071-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9517357-B2
priorityDate 2007-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007187862-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005012606-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006121080-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004062697-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006030927-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003088307-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006167540-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395632
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID36314
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538410
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396057
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID702
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCO01945
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136045608
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284616
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454240270
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID25212
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID478951

Total number of triples: 41.